Page 12 - Haematologica May 2020

1172
Editorials
Recruiting TP53 to target chronic myeloid leukemia stem cells
Steven Grant
Virginia Commonwealth University, Richmond, VA, USA E-mail: STEVEN GRANT - steven.grant@vcuhealth.org
doi:10.3324/haematol.2019.246306
The problem of eradicating leukemic stem cells (LSC) in chronic myeloid leukemia (CML), as in the case of acute myelogenous leukemia (AML), has long been a therapeutic goal, particularly in relation to agents such as tyrosine kinase inhibitors (TKI), such as imatinib mesylate (IM), that target the oncogenic BCR/ABL kinase. The central conundrum is that CML stem cells appear to be intrinsically resistant to TKI through a variety of mechanisms, including (but not restricted to) increased drug efflux pumps1 or persistence in a drug-resistant quiescent state. The failure of IM or newer-generation TKI to eradicate CML stem cells pre- sumably underlies the development of drug resistance and/or progression to a more aggressive clinical course e.g. accelerated or blast-phase disease. This inevitable outcome (in transplant-ineligible patients) has prompted the search for new therapeutic strategies capable of elim- inating the subset of TKI-resistant stem cells.
In the article by Carter et al., which appears in this edi- tion of Haematologica,2 the authors expand upon their previous work investigating novel strategies specifically capable of targeting CML LSC. This group had previously shown that the BH3 mimetic Venetoclax (ABT-199), an agent now approved (in combination with hypomethy- lating agents) in older AML patients, targets LSC, and, when administered in conjunction with IM, effectively eradicated CML stem cells.3 This group had also shown that disrupting the function of MDM2 (e.g. with nutlin), a protein that binds to and inactivates TP53,4 also enhanced the activity of IM in a CML blast crisis model. The mechanism(s) by which activating TP53 might sensi- tize CML stem cells to IM remains to be fully elucidated, but very likely reflects induction of downstream TP53 pro-apoptotic effectors such as NOXA, PUMA, BAX, and BID. For example, NOXA is known to trigger degradation of anti-apoptotic proteins such as MCL-1,5 which have been shown to serve as a survival factor for leukemia stem cells.6
In the present study, the authors examined the effects of a newer MDM2 antagonist (DS-5272) on the sensitivi- ty of CML stem cells to IM using an inducible stem cell promoter-driven CML murine model (Scl-tTa-BCR/ABL1). Employing CyTOF-based single-cell proteomics, they found that combined BCR/ABL1 and MDM2 inhibition resulted in the selective upregulation of NOXA and BAX in the CML-LSC population. Importantly, the combina- tion strategy was effective in prolonging survival in this mouse model and in decreasing CML LSC frequency in secondary transplantations. The authors conclude that CML LSC may depend upon TP53 hyperactivation for survival, and that disruption of this process e.g. by MDM2 antagonism may restore TKI sensitivity in these cells. A schematic summary of these concepts is shown in Figure 1. According to this model, CML LSC exhibit rela-
tive resistance to TKI, but high activity of TP53, the lethal effects of which are kept in check by MDM2. Disabling of the latter process, e.g. by MDM2 antagonists, results in increased expression of pro-apoptotic TP53-dependent proteins, e.g. NOXA and BAX, which lower the threshold for TKI-mediated cell death (Figure 1A). Activation of TP53 may also lead to downregulation of anti-apoptotic proteins such as MCL-1 indirectly through induction of NOXA. Alternatively, pro-apoptotic proteins such as BCL-2 may be disabled by small molecule BH3-mimetics such as ABT-199, analogously promoting TKI-induced cell death (Figure 1B). The net effect of these events is the selective eradication of CML LSC, an outcome unlikely to be accomplished with TKI alone.
If validated, these findings could have significant impli- cations for the treatment of chronic phase CML by raising the possibility that concomitant administration of MDM2 antagonists with a TKI such as IM might, by tar- geting quiescent CML stem cells, delay or prevent the emergence of AP or BC. The success of this strategy will be contingent upon the presence of functioning TP53, as the results of earlier studies, as well as this present one, argue strongly that activation of this oncogene is essential for the beneficial actions of MDM2 antagonists. One implication of these findings is that early incorporation of MDM2 inhibitors into TKI-based therapies for CML may be necessary for optimal benefit. For example, in the case of AML, loss of functional TP53 occurs late in the disease and is associated with a particularly poor prognosis.7 Thus, early eradication of CML stem cells through such a TP53-based strategy may forestall or circumvent the emergence of aggressive clones that have lost functional TP53. Furthermore, while Carter et al. have previously described the capacity of the TKI/MDM2 antagonist strategy to target BC cells,8 the later this approach is applied, the greater the chance of the development of TP53-deficient cells that are resistant to its lethal activity.
One question that arises concerns the mechanism(s) by which addition of an MDM2 antagonist might enhance the activity of TKI against CML stem cells. As noted pre- viously, CML LSC tend to be resistant to TKI because of several factors, including their quiescent state, as well as increased drug efflux in this cell population.9 To date, there is no evidence that MDM2 inhibitors can directly circumvent these mechanisms and as a consequence, restore TKI sensitivity. Instead, the former agents may primarily operate to modulate the apoptotic threshold e.g. by inducing NOXA, BAX, and potentially other TP53-dependent pro-apoptotic effectors.10 The ability of the combined TKI/MDM2 antagonist regimen to display superior LSC killing argues that this strategy acts, at least in part, to potentiate the ability of TKI to induce cell death rather than to overcome intrinsic TKI resistance in primitive leukemia progenitors.
haematologica | 2020; 105(5)